Evidence map›Paper›PMID 29315477›Full record

ArticleBiotechnology and bioengineering2018

Enrichment of high affinity subclasses and glycoforms from serum-derived IgG using FcγRs as affinity ligands.

Austin W Boesch, James H Kappel, Alison E Mahan, Thach H Chu, Andrew R Crowley, Nana Y Osei-Owusu, Galit Alter, Margaret E Ackerman

Abstract read
In one paragraph

Article in Biotechnology and bioengineering, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Antibodies for Human Immunodeficiency Virus-1 Cure Strategies.The Journal of infectious diseases · 2021
    Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Austin W BoeschThayer School of Engineering, Dartmouth College, Hanover, New Hampshire.
James H KappelThayer School of Engineering, Dartmouth College, Hanover, New Hampshire.
Alison E MahanRagon Institute of MGH, MIT, and Harvard University, Cambridge, Massachusetts.
Thach H ChuThayer School of Engineering, Dartmouth College, Hanover, New Hampshire.
Andrew R CrowleyDepartment of Microbiology and Immunology, Geisel School of Medicine, Hanover, New Hampshire.
Nana Y Osei-OwusuDepartment of Microbiology and Immunology, Geisel School of Medicine, Hanover, New Hampshire.
Galit AlterRagon Institute of MGH, MIT, and Harvard University, Cambridge, Massachusetts.
Margaret E AckermanThayer School of Engineering, Dartmouth College, Hanover, New Hampshire.ORCID 0000-0002-4253-3476

Funding

Physical Resources CoreP01AI120756 · NIAID · DUKE UNIVERSITY · PI TOMARAS, GEORGIA DORIS · 2016 to 2020
$17.1M
Directing Antibody Effector Activity via Controlled IgG Subclass SwitchingR01AI131975 · NIAID · DARTMOUTH COLLEGE · PI ACKERMAN, MARGARET E · 2017 to 2020
$2.6M
Applying High-Performance Protein Engineering Tools to HIV Immunogen DesignR01AI102691 · NIAID · DARTMOUTH COLLEGE · PI ACKERMAN, MARGARET E · 2012 to 2015
$2.2M
NIAID NIH HHS P01 AI120756NIAID NIH HHS R01 AI102691NIAID NIH HHS R01 AI131975
6 · The paper itself

Abstract

As antibodies continue to gain predominance in drug discovery and development pipelines, efforts to control and optimize their activity in vivo have matured to incorporate sophisticated abilities to manipulate engagement of specific Fc binding partners. Such efforts to promote diverse functional outcomes include modulating IgG-Fc affinity for FcγRs to alternatively potentiate or reduce effector functions, such as antibody-dependent cellular cytotoxicity and phagocytosis. While a number of natural and engineered Fc features capable of eliciting variable effector functions have been demonstrated in vitro and in vivo, elucidation of these important functional relationships has taken significant effort through use of diverse genetic, cellular and enzymatic techniques. As an orthogonal approach, we demonstrate use of FcγR as chromatographic affinity ligands to enrich and therefore simultaneously identify favored binding species from a complex mixture of serum-derived pooled polycloncal human IgG, a load material that contains the natural repertoire of Fc variants and post-translational modifications. The FcγR-enriched IgG was characterized for subclass and glycoform composition and the impact of this bioseparation step on antibody activity was measured in cell-based effector function assays including Natural Killer cell activation and monocyte phagocytosis. This work demonstrates a tractable means to rapidly distinguish complex functional relationships between two or more interacting biological agents by leveraging affinity chromatography followed by secondary analysis with high-resolution biophysical and functional assays and emphasizes a platform capable of surveying diverse natural post-translational modifications that may not be easily produced with high purity or easily accessible with recombinant expression techniques.

Indexed as

Biological ProductsChromatography, AffinityHumansImmunoglobulin GImmunologic FactorsReceptors, IgGTechnology, PharmaceuticalBiological ProductsImmunoglobulin GImmunologic FactorsReceptors, IgGantibodyFc receptorglycosylationIgGpost-translational modification

Identifiers

PMID29315477
PMCPMC5906797

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.